Adocia SA · EURONEXT:ADOC

Adocia SA — Investor Presentation (May 2018)

40 slides from Adocia SA's investor presentation, May 2018

  1. Slide 1: Adocia Corporate Presentation

    Slide 1: Adocia Corporate Presentation

    ADOCIA CORPORATE PRESENTATION May 2018

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    INTRO Disclaimer This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying t

  3. Slide 3: ADOCIA in summary

    Slide 3: ADOCIA in summary

    ADOCIA ADOCIA in summary Business model delivering cost-effective innovation based on already-approved 1 proteins, enhanced with BioChaperone® Key clinical assets including ultra-rapid insulin BC Lispro, modern premix BC 2 Combo, ready-to-use BC Glucagon and BC Pramlintide Insulin 3 $135M licensing

  4. Slide 4: Management Team

    Slide 4: Management Team

    ADOCIA Management Team Gérard Soula Olivier Soula Valérie Rémi Soula Steve Daly PhD, MBA PhD, MBA Danaguezian PhD, MBA President & CEO Deputy General Manager, Chief Financial Officer Director of BD & IP US General Manager Co-founder R&D Director Co-founder Co-founder 4 May 2018

  5. Slide 5: Our mission is dedicated to improving lives

    Slide 5: Our mission is dedicated to improving lives

    ADOCIA Our mission is dedicated to improving lives Develop treatments for diabetes and other metabolic conditions in a more physiologic and affordable way 5 May 2018

  6. Slide 6: BioChaperone Technology

    Slide 6: BioChaperone Technology

    BIOCHAPERONE TECHNOLOGY 6 May 2018

  7. Slide 7: BioChaperone unlocks the potential of proteins and peptides

    Slide 7: BioChaperone unlocks the potential of proteins and peptides

    ADOCIA BioChaperone® unlocks the potential of proteins and peptides and their combinations in a cost-effective way BioChaperone® Proteins and peptides (insulin, GLP-1 RA, pramlintide, (library of molecules) glucagon; teduglutide…) [BioChaperone® Protein] Complex  Improved solubility Improved stabi

  8. Slide 8: Adocia is diversifying its portfolio beyond diabetes

    Slide 8: Adocia is diversifying its portfolio beyond diabetes

    ADOCIA Adocia is diversifying its portfolio beyond diabetes Diabetes clinical pipeline Preclinical pipeline In vitro PC Phase I/II Phase III In vitro PC Phase I/II BC Lispro U100 Diabetes THDB BC Lispro U200 BC Gla GLP-1 THDB BC Combo Other indications (BC Gla Lis) BC GLP-2 Short Bowel Syndrome Hins

  9. Slide 9: There remains a real medical need in diabetes

    Slide 9: There remains a real medical need in diabetes

    DIABETES There remains a real medical need in diabetes 26M2  Despite 100 years of medical treatment, long-term 415M1 on insulin consequences of diabetes remain a major issue people with diabetes in 2015  There is a need to address the underlying complexity of diabetes  With more granularity  In

  10. Slide 10: Diabetes in China

    Slide 10: Diabetes in China

    CHINA Diabetes in China  Chinese treated partients expected to double (from 30 to 60M) in the next 5-7 years3 >100M1  Better diagnosis, better reimbursements, stronger access in remote areas People with diabetes in China  Insulin market (CAGR 12%)2 currently dominated by premix insulins  Tonghua

  11. Slide 11: BioChaperone Lead Insulin Clinical Programs

    Slide 11: BioChaperone Lead Insulin Clinical Programs

    BIOCHAPERONE LEAD INSULIN CLINICAL PROGRAMS BIOCHAPERONE LISPRO & BIOCHAPERONE COMBO 11 May 2018

  12. Slide 12: BioChaperone Lispro: an ultra-rapid insulin

    Slide 12: BioChaperone Lispro: an ultra-rapid insulin

    BC LISPRO BioChaperone Lispro: an ultra-rapid insulin showing potential best-in-class performance in pens and pumps $7B  Novo Nordisk Fiasp® (faster-acting insulin aspart) is the first approved product Prandial  Introduced at price parity with Novolog® in Europe insulin market  Approved in the US

  13. Slide 13: Partnering BioChaperone Lispro is Adocia's priority

    Slide 13: Partnering BioChaperone Lispro is Adocia's priority

    BC LISPRO Partnering BioChaperone Lispro is Adocia’s priority  BC Lispro (U100 & U200) has a complete dossier to support Post-meal glycaemia in T1D Phase 3  Accelerated absorption and better post-prandial control for BC Lispro U100 vs. Humalog®  vs. Fiasp®, BC Lispro has shown similar fast-on eff

  14. Slide 14: BC Combo: a safer alternative to premix insulin

    Slide 14: BC Combo: a safer alternative to premix insulin

    BC COMBO A safer and more efficient alternative to premix insulin for the treatment of type 2 diabetes  Premix insulin provides basal and prandial coverage with 2 injections/day $5B (vs. up to 4 for basal + prandial insulin) 65%1 Premix insulin  In China, premix is the main insulin product in volu

  15. Slide 15: BC Combo superior prandial and basal control vs premix

    Slide 15: BC Combo superior prandial and basal control vs premix

    BC COMBO BC Combo has shown superior prandial and basal control compared to premix insulin Post-meal glycemia in T1D  5 successful Phase 1/2 clinical studies (2 in T1D & 3 in T2D)(1,2) Individualized doses  In T1D & T2D BC Combo showed superiority vs. Humalog Mix25 (1,2): ∆AUC0-2h  In T2D, BC Com

  16. Slide 16: Multihormonal Treatments for Diabetes

    Slide 16: Multihormonal Treatments for Diabetes

    MULTIHORMONAL TREATMENTS FOR DIABETES 16 May 2018

  17. Slide 17: Innovative multi-hormonal approaches for diabetes and obesity

    Slide 17: Innovative multi-hormonal approaches for diabetes and obesity

    RATIONALE Innovative multi-hormonal approaches aim to improve diabetes and obesity management Insulin In combination BC Glargine GLP-1 (T2D) BC Pramlintide rhIns (T1D & T2D) GLP-1 Amylin In combination In a dual-chamber pump BC Glucagon GLP-1 BC Glucagon with Insulin (T1D) (Obesity) Glucagon As a se

  18. Slide 18: Time-sensitive hormonal pattern maintains normo-glycemia

    Slide 18: Time-sensitive hormonal pattern maintains normo-glycemia

    DIABETES In non-diabetic people, a time-sensitive hormonal pattern maintains normo-glycemia Schematic representation of hormonal pattern1 Insulin Without diabetes With Type 1 diabetes (T1D) Level of secretion Amylin (relative scale) Glucagon GLP-1 GLP-1 Glucagon Insulin Amylin 0 1 2 3 4 5 6 0 1 2 3

  19. Slide 19: Amylin, the Other Missing Hormone in Type 1 Diabetes

    Slide 19: Amylin, the Other Missing Hormone in Type 1 Diabetes

    BC PRAM INS Amylin, the Other Missing Hormone in Type 1 Diabetes Postprandial blood glucose 6  Amylin is co-secreted with insulin by pancreatic beta cells. h u m a n in s u lin in c re m e n ta l p la s m a g lu c o s e ( m m o l/L ) 5 h u m a n in s u lin + a m y lin a n a lo g 4  Secretion of Am

  20. Slide 20: Benefits of co-administering prandial insulin with pramlintide

    Slide 20: Benefits of co-administering prandial insulin with pramlintide

    BC PRAM INS Leveraging the clinically proven benefits of co-administering prandial insulin with pramlintide -3 kg1 -22%1  Pramlintide (amylin analog) three times a day has demonstrated synergistic benefits when administered on top of insulin2 Blood glucose control (T1D)  Better glycemic control vs

  21. Slide 21: Multi-hormonal treatment to improve long-term outcomes in T1D

    Slide 21: Multi-hormonal treatment to improve long-term outcomes in T1D

    BC PRAM INS Enabling prandial insulin-based multi-hormonal treatment to improve long-term outcomes in T1D  Tighter glycemic control lowers the risk of severe complications1, and insulin alone, while life-saving, is insufficient to optimize control  Multiple hormonal combinations could be the next

  22. Slide 22: Ready-to-use aqueous formulation of human glucagon

    Slide 22: Ready-to-use aqueous formulation of human glucagon

    BC GLUCAGON A ready-to-use aqueous formulation of human glucagon for acute and chronic use  BioChaperone Glucagon is an aqueous formulation of human glucagon supporting:  Ready-to-use rescue treatment for severe hypoglycemia  Current market largely underserved due to poor glucagon kits usability1

  23. Slide 23: Positive first-in-man data support further development

    Slide 23: Positive first-in-man data support further development

    BC GLUCAGON Positive first-in-man data support further development  Positive first-in-man results. : 180 Preclinical study in pigs  Be safe and well tolerated in people with type 1 diabetes Mean blood glucose  Efficiently rescue 100% participants from medically-induced Blood Glucose (mg/dL) 160 h

  24. Slide 24: Expanding the Portfolio

    Slide 24: Expanding the Portfolio

    EXPANDING THE PORTFOLIO LEVERAGING BIOCHAPERONE TRACK-RECORD TO ADDRESS NEW THERAPEUTIC TARGETS 24 May 2018

  25. Slide 25: Leveraging BioChaperone beyond diabetes

    Slide 25: Leveraging BioChaperone beyond diabetes

    PORTFOLIO EXPANSION Adocia is leveraging BioChaperone® to unlock the potential of proteins and peptides beyond diabetes  Adocia intends to expand the use of BioChaperone to bring cost-effective innovation to other therapeutic areas with high unmet needs by leveraging:  Extensive BioChaperone® trac

  26. Slide 26: BioChaperone Glucagon-GLP-1 for nondiabetic obesity

    Slide 26: BioChaperone Glucagon-GLP-1 for nondiabetic obesity

    BC GCG GLP-1 BioChaperone Glucagon-GLP-1 for the treatment of nondiabetic obesity  Obesity prevalence has tripled from 1975 to 2016 globally2, triggering the development of more aggressive treatment regimens: 36.5%1  Based on BioChaperone Glucagon, Adocia has developed injectable combinations of o

  27. Slide 27: BioChaperone GLP-2 for short-bowel syndrome

    Slide 27: BioChaperone GLP-2 for short-bowel syndrome

    BC GLP-2 BioChaperone GLP-2: a ready-to-use solution to improve the life of people with short-bowel syndrome (SBS)  Approx. 20,000 people with SBS require parenteral nutrition in EU & US1  Prevalence and awareness are growing  Gattex® (teduglutide, Shire) is the only approved treatment for these

  28. Slide 28: Key financial elements

    Slide 28: Key financial elements

    ADOCIA Key financial elements Financial summary Shareholders’ equity (March 2018) Analysts  Listed on Euronext Paris (ADOC) Free Float Soula Family 22.1 %  Jefferies (Peter Welford) 60.0%  Kepler Market (Arsène Guekam)  6.9M shares outstanding  Oddo (Sébastien Malafosse – Pierre Corby)  Louis

  29. Slide 29: Key assets status

    Slide 29: Key assets status

    ADOCIA Key assets status Clinical programs Preclinical programs  BC LISPRO  Phase 3-ready asset, available for licensing in US, EU, Japan  BC GLUCAGON GLP-1 Partnered with Tonghua Dongbao in April 2018 for China and other  First-in-man study planned in Q4 18 New! emerging markets  Positive Pha

  30. Slide 30: Thank you for your kind interest

    Slide 30: Thank you for your kind interest

    THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 30 May 2018

  31. Slide 31: Appendix

    Slide 31: Appendix

    APPENDIX 31 May2018 ADOCIA f-

  32. Slide 32: Top-tier Medical Advisory Board

    Slide 32: Top-tier Medical Advisory Board

    ADOCIA Adocia is supported by a top-tier Medical Advisory Board  12 highly renowned international thought-leaders:  Dr. Jay Skyler, MD, Chairman, University of Miami (US)  Dr. Vanita Aroda, MD, MedStar Health Research Institute (US)  Dr. Bruce Bode, MD, Emory University (US)  Dr. John Buse, MD,

  33. Slide 33: HinsBet: Affordable prandial insulin

    Slide 33: HinsBet: Affordable prandial insulin

    HINSBET Affordable prandial insulin for price-sensitive populations  HinsBet is a formulation of human insulin designed to act as rapidly as an insulin analog $1B  77% of people with diabetes live in low- and middle-income countries Human prandial  For economic reasons, human insulin is the most

  34. Slide 34: HinsBet displays similar early action to fast-acting analog

    Slide 34: HinsBet displays similar early action to fast-acting analog

    HINSBET HinsBet displays similar early action to fast-acting insulin analog in T1D patients Early Glucose Infusion Rate (U100)1  Meal-test study in 36 T1D confirmed PD profile in first hour2 (Oct 2016)  During first hour after the meal, HinsBet:  70% earlier onset  Significantly reduced glucose

  35. Slide 35: Intensification options over basal insulin for T2D

    Slide 35: Intensification options over basal insulin for T2D

    BC GLAR GLP-1 Efficient and affordable intensification options over basal insulin for T2D $2.2B1  Combinations of basal insulin and GLP-1 are a new class of treatment for T2D 2023 Forecast  50% patients are not controlled on basal insulin alone2 Basal-GLP1  2 products recently approved in EU & US

  36. Slide 36: BC Lispro results vs Humalog U100 in T1DM

    Slide 36: BC Lispro results vs Humalog U100 in T1DM

    BC LISPRO Results summary compared to Humalog U100 in T1DM subjects 294-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Biochaperone Lispro: Shorter TMAX, Higher CMAX  BioChaperone Lispro in comparison with and Similar Exposure Greater Earlier Exposure: Faster In Humalo

  37. Slide 37: BC Combo results vs Lispro Mix 75/25 in T1DM

    Slide 37: BC Combo results vs Lispro Mix 75/25 in T1DM

    BC COMBO Results summary compared to Conventional Lispro Mix 75/25 in T1DM subjects 295-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Mean Unadjusted BG Profiles ± SEM Over 6hr After s.c. Cumulative Percentage of Subjects With BG Values < 63 mg/dL  In this solid mixed

  38. Slide 38: BC Combo results vs Humalog 75/25 in T2DM

    Slide 38: BC Combo results vs Humalog 75/25 in T2DM

    BC COMBO Results summary compared to Humalog 75/25 in T2DM subjects 942-P in 12-B Clinical Therapeutics/ New Technology-Insulins, June 11, 2016, 76th ADA Scientific Sessions Smoothed GIR Profiles (0-30h) of 0.8 U/kg BioChaperone Combo, 0.8 Smoothed GIR Profiles (0-2h) of 0.8 U/kg BioChaperone  In t

  39. Slide 39: Upcoming major diabetes conferences

    Slide 39: Upcoming major diabetes conferences

    EVENTS Upcoming major diabetes conferences  Adocia will submit abstracts for publication and intends to attend the following conferences:  78th Scientific Sessions of the American Diabetes Association, June 22 - 26, 2018, Orlando, Florida, USA  54th Annual Meeting of the European Association for

  40. Slide 40: Thank you for your kind interest

    Slide 40: Thank you for your kind interest

    THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 40 May 2018

Source: Internet Archive copy of adocia.com

More decks from Adocia SA

All 49 Adocia SA decks